Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression levels of SPDL1 mRNA in PAAD tumors and normal tissues. A SPDL1 mRNA expression in TCGA cohort. B SPDL1 mRNA expression in GSE15471 cohort. C SPDL1 mRNA expression in GSE62165 cohort. D The graph presents a bar chart of SPDL1 expression distribution across PAAD cell lines, Both the height and color of the bars indicate the magnitude of SPDL1 expression, with the median serving as the cutoff point. P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Representative immunohistochemical images showing SPDL1 expression in tumor-adjacent tissues and pancreatic adenocarcinoma (PAAD) tissues. A SPDL1 staining in adjacent tissues. B SPDL1 weak staining in PAAD tissues. C SPDL1 strong staining in PAAD tissues. The expression of SPDL1 in PAAD tissues with different Ki-67 expression. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Single-cell expression analysis of SPDL1 in PAAD. A The UMAP plot of single-cell clustering in GSE148673 . B UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE148673 . C AUCell score for tumor proliferation signature in different cells in GSE148673 . D The UMAP plot of single-cell clustering in GSE154778 . E UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE154778 . F AUCell score for tumor proliferation signature in different cells in GSE154778 . G SPDL1 expression across distinct cell types in GSE148673 . H Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673 . I SPDL1 expression across distinct cell types in GSE148673 . J Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Single Cell, Expressing, Protein-Protein interactions

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: The correlation of SPDL1 mRNA expression with clinical parameters from the TCGA cohort, including ( A ) Age, ( B ) Sex, ( C ) T stage, ( D ) N stage, ( E ) M stage, ( F ) TNM stage. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression is associated with the prognosis of PAAD patients. A Kaplan-Meier survival curves of OS between high and low SPDL1 expression groups. B Kaplan-Meier survival curves of DSS between high and low SPDL1 expression groups. C Kaplan-Meier survival curves comparing PFI between high and low SPDL1 expression groups. D Univariate and Multivariate Cox regression analysis (overall survival) for prognostic factors in PAAD. E Independent risk factors were evaluated for OS using multivariate Cox regression and were combined into the nomogram model. F ROC curves and nomogram AUC values for predicting 1-, 2-, and 3-year OS. G Calibration charts for the nomogram depicting 1-year, 2-year and 3-year OS. H DCA for the nomogram depicting 1-year OS. I DCA for the nomogram depicting 2-year OS. J DCA for the nomogram depicting 3-year OS

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: GSEA and GSVA analysis. A GSEA analysis revealed that the tumor proliferation pathway is enriched in the SPDL1-high expression group. B Relationship between SPDL1 expression and tumor proliferation score

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Effect of SPDL1 Silencing on PAAD Cell Proliferation in PAAD. A Western blot analysis showing that SPDL1 protein expression was significantly reduced in PANC-1 cells following transfection with si-SPDL1 compared with control group. B CCK-8 assays demonstrated that SPDL1 silencing markedly inhibited cell viability in PANC-1 cells over time (24, 48, and 72 h), with significant reduction at 24 h compared with control group. C , D Colony formation assays indicated that SPDL1 knockdown significantly reduced the number of colonies formed. E , F EdU incorporation assay reveals SPDL1 knockdown significantly reduced the ratio of cell proliferation. For ( A ), ( B ), ( D ), and ( E ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Western Blot, Expressing, Transfection, Control, CCK-8 Assay, Knockdown

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Knockdown expression of SPDL1 inhabited the migration and invasion of PANC-1 cells. A Wound healing assays showed that SPDL1 knockdown significantly delayed wound closure at 24 h, indicating impaired migration. B Transwell invasion assays showed that SPDL1 silencing significantly decreased the number of invading PANC-1 cells. For ( A ) and ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Knockdown, Expressing, Migration

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: SPDL1 activates the AKT/mTOR signaling pathway. A Gene Set Enrichment Analysis (GSEA) based on TCGA dataset revealed that the PI3K/AKT/mTOR signaling pathway was significantly enriched in the SPDL1 high-expression group relative to the SPDL1 low-expression group. B Western blot assay was performed to detect the protein expression levels of AKT, phosphorylated AKT (p-AKT), mTOR, and phosphorylated mTOR (p-mTOR) in PANC-1 cells following different transfection treatments. For ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing, Western Blot, Transfection

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 6. Anti-MICA/B 7C6 mAb boosts anti-tumor cytotoxic function of peripheral NK cells from iCCA patients against the HuCCT-1 cell line. A): peripheral NK cell degranulation, evaluated as frequency of CD107a+ NK cells, in iCCA patients (n = 13) and HC (n = 16) in the presence of 7C6 mAb or IgG1-Fc. Parametric paired and unpaired t tests were used to compare data. B): dot plots showing the frequency of CD3-CD56+ CD107a+ NK cells in a HC and a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc. C): the proportion of circulating IFNγ+ NK cells in patients (n = 10) and HC (n = 11) in the presence of 7C6 mAb compared with IgG1-Fc. To compare paired data, the parametric t test and the non-parametric Wilcoxon t test were used. To compare unpaired data, the parametric t test and the non-parametric Mann-Whitney U test were used. D): representative dot plots showing the frequency of CD3-CD56+ IFNγ+ NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: MANN-WHITNEY

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 7. Anti-MICA/B 7C6 mAb boosts anti-tumor cytotoxic function of peripheral NK cells from iCCA patients against patient-derived iCCA cell lines. A): peripheral NK cell degranulation, evaluated as CD107a+NK frequency, in iCCA patients (n = 12) and HC (n = 8) in the presence of 7C6 mAb or IgG1-Fc using patient- derived primary tumor cell lines as targets. Parametric paired and unpaired t tests were used to compare data. B): dot plots showing the frequency of CD3-CD56 + CD107a+ NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc. C): proportion of circulating IFNγ+NK cells in patients (n = 10) and in HC (n = 8) in the presence of 7C6 mAb compared with IgG1-Fc. To compare paired data, we used the parametric t test and the non-parametric Wilcoxon t test. To compare unpaired data, the parametric t test and the non-parametric Mann-Whitney U test were used. D): representative dot plots showing the frequency of CD3-CD56+ IFNγ +NK cells in a HC and in a patient (iCCA) in the presence of 7C6 mAb or IgG1-Fc.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Derivative Assay, MANN-WHITNEY

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 8. 7C6 mAb enhances the anti-tumor effect of liver- and tumor-infiltrating NK cells in iCCA patients. A): Frequency of degranulating CD107a+NK cells in LIL (n = 13) and TIL (n = 10) of iCCA patients in the presence of anti-MICA/B 7C6 mAb or IgG1-Fc using autologous tumor-derived cell lines as targets. Parametric paired and unpaired t tests were used to compare data. B): representative dot plots showing the frequency of CD3-CD56+ CD107a+ LIL- and TIL-NK cells in the presence of 7C6 mAb or IgG1-Fc. C): proportion of IFNγ+ NK cells in LIL (n = 10) and TIL (n = 8) of iCCA patients in the presence of 7C6 mAb compared with IgG1-Fc using autologous tumor-derived cell lines as targets. The parametric t test and non-parametric Wilcoxon t test were used to compare paired data. The parametric t test was used to compare unpaired data.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Derivative Assay

Journal: OncoImmunology

Article Title: MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma

doi: 10.1080/2162402x.2022.2035919

Figure Lengend Snippet: Figure 9. Cytotoxicity assay of HC PBMC, patient PBMC, LIL and TIL cells. A, B): Frequency of CFSE+LIVE/DEAD (LD)+ HuCCT-1 cell line targets when HC PBMC (n = 5), patient PBMC (n = 10), LIL (n = 8) and TIL (n = 5) were used as effector cells in the presence of 7C6 mAb and isotype control (IgG1). The parametric paired t tests were used to compare data. C, D): Frequency of CFSE+LD+ patient-derived cell line targets when HC PBMC (n = 5), patient PBMC (n = 8), LIL (n = 8) and TIL (n = 4) were used as effectors in the presence of 7C6 and isotype control. The parametric paired t test was used to compare data in panel C. The non-parametric Wilcoxon t test was used to compare paired data in panel D. Target cell death was determined as frequency of CFSE+LD+ cells.

Article Snippet: The recombinant human IgG1 Fc (BioXcell, Lebanon, NH, USA) and the humanized anti-MICA/B 7C6-IgG1 mAb were added at a final concentration of 10 μg/ml.

Techniques: Cytotoxicity Assay, Control, Derivative Assay